SRPT Sarepta Therapeutics Inc.

139.98
+3.44  (+3%)
Previous Close 136.54
Open 137.5
Price To Book 14.61
Market Cap 9353970888
Shares 66,823,624
Volume 776,270
Short Ratio
Av. Daily Volume 1,063,586

NewsSee all news

  1. Sarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019
  2. 3 Top Biotech Stocks to Buy in February
  3. Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
  4. Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)
  5. Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604166
  3. 8-K - Current report 19601146
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595125
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19593653

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial ongoing. Mid-2019 regulatory filing expected.
Casimersen (SRP-4045) - ESSENCE
Duchenne muscular dystrophy
Phase 1/2 updated data released October 3, 2018.
Microdystrophin gene therapy
Duchenne muscular dystrophy
Phase 1 trial safety and dosing insight due 1Q 2019.
SRP-5051 - PPMO
Duchenne muscular dystrophy
PDUFA date under priority review August 19, 2019 .
Golodirsen - Exon 53
Duchenne muscular dystrophy
Approved September 19, 2016.
Eteplirsen - Exon 51
Duchenne muscular dystrophy
Phase 1 trial ongoing.
MYO-201
Duchenne muscular dystrophy - LGMD2D
Phase 1/2 complete. Protocol update enabling IV delivery Phase 1/2a trial planned 2018
MYO-102
Duchenne muscular dystrophy - (LGMD2B)
Phase 1/2 data due February 27, 2019. CC 8am EST.
MYO-101
Duchenne muscular dystrophy - LGMD2E
Phase 2/3 initiation of dosing announced February 14, 2019.
LYS-SAF302
Mucopolysaccharidosis type IIIA (MPS IIIA)

Latest News

  1. Sarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019
  2. 3 Top Biotech Stocks to Buy in February
  3. Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
  4. Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)
  5. Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
  6. Weekly CFO Sells Highlight
  7. Implied Volatility Surging for Sarepta (SRPT) Stock Options
  8. See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
  9. What Solid Biosciences' First Failure Means for Sarepta Therapeutics
  10. Solid Biosciences shares drop 70% on disappointing Duchenne data
  11. Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains
  12. 3 Gene Therapy Stocks With Huge Catalysts in 2019
  13. Should You Take Comfort From Insider Transactions At Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?
  14. 6 Biotech Stocks to Watch Now
  15. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  16. Fear of Missing Out Is the Main Driving Force in This Market
  17. Your first trade for Thursday, January 31
  18. Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sarepta Therapeutics

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604166
  3. 8-K - Current report 19601146
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595125
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19593653
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19572467
  7. 8-K - Current report 19512595
  8. 8-K - Current report 181244716
  9. 8-K - Current report 181227849
  10. S-8 - Securities to be offered to employees in employee benefit plans 181224120